4//SEC Filing
Mallon Mark 4
Accession 0001209191-20-012528
CIK 0001446847other
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 4:45 PM ET
Size
7.0 KB
Accession
0001209191-20-012528
Insider Transaction Report
Form 4
Mallon Mark
DirectorChief Executive Officer
Transactions
- Sale
Class A Common Stock
2020-02-21$11.63/sh−7,983$92,842→ 303,426 total - Sale
Class A Common Stock
2020-02-24$11.25/sh−1$11→ 303,425 total
Footnotes (2)
- [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 9, 2019.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Documents
Issuer
IRONWOOD PHARMACEUTICALS INC
CIK 0001446847
Entity typeother
Related Parties
1- filerCIK 0001763533
Filing Metadata
- Form type
- 4
- Filed
- Feb 24, 7:00 PM ET
- Accepted
- Feb 25, 4:45 PM ET
- Size
- 7.0 KB